FDA clears EKG accessory for Apple Watches

The FDA recently cleared AliveCor’s electrocardiogram accessory for the Apple Watch, the Mountain View, Calif.-based company announced Nov. 30.

Advertisement

AliveCor, a developer of personal EKG gadgets, released KardiaBand as a medical app for Apple Watch users. KardiaBand, which enables users to take 30-second EKG readings, displays heart rhythm findings on the face of the smartwatch.

The company also introduced an artificial intelligence feature called SmartRhythm within the app Nov. 30. SmartRhythm continuously evaluates a user’s heart rate alongside the Apple Watch’s activity sensors. When these values are out of sync, the app encourages users to capture an EKG reading, according to AliveCor officials.

“These capabilities will allow people to easily and discreetly check their heart rhythms when they may be abnormal, capturing essential information to help doctors identify the issue and inform a clear path of care to help manage [atrial fibrillation], a leading cause of stroke, and other serious conditions,” said Vic Gundotra, CEO of AliveCor.

More articles on supply chain:
WHO: 1 in 10 drugs in poor countries are counterfeit, ineffective
CVS launches ‘real-time benefits’ tool to increase price transparency
Sun Pharma recalls diabetes drug due to fungal contamination

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Rethinking Safety and Security in the Healthcare Environment

Thursday, July 23
1:00 PM - 2:00 PM CDT

Presenters: Jon Share, AxonDan Snyder, Advocate HealthKeith Hunter, Wellstar

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.